Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
AUROBINDO PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-24 |
TEVA PHARMA Dec-13 |
AUROBINDO PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,177 | 3,528 | - | |
Low | Rs | 517 | 3,065 | - | |
Sales per share (Unadj.) | Rs | 495.0 | 2,024.7 | - | |
Earnings per share (Unadj.) | Rs | 54.1 | 126.5 | - | |
Cash flow per share (Unadj.) | Rs | 80.1 | 290.1 | - | |
Dividends per share (Unadj.) | Rs | 4.50 | 110.72 | - | |
Avg Dividend yield | % | 0.5 | 3.4 | 15.8% | |
Book value per share (Unadj.) | Rs | 509.3 | 2,249.0 | - | |
Shares outstanding (eoy) | m | 585.94 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.7 | 1.6 | 105.1% | |
Avg P/E ratio | x | 15.7 | 26.1 | 60.1% | |
P/CF ratio (eoy) | x | 10.6 | 11.4 | 93.1% | |
Price / Book Value ratio | x | 1.7 | 1.5 | 113.5% | |
Dividend payout | % | 8.3 | 87.5 | 9.5% | |
Avg Mkt Cap | Rs m | 496,290 | 2,795,245 | 17.8% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 39,229 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 38,200.9 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,386.4 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 290,019 | 1,716,939 | 16.9% | |
Other income | Rs m | 5,574 | 0 | - | |
Total revenues | Rs m | 295,593 | 1,716,939 | 17.2% | |
Gross profit | Rs m | 56,340 | 470,185 | 12.0% | |
Depreciation | Rs m | 15,217 | 138,782 | 11.0% | |
Interest | Rs m | 2,897 | 33,723 | 8.6% | |
Profit before tax | Rs m | 43,800 | 297,679 | 14.7% | |
Minority Interest | Rs m | 0 | 1,352 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -195,410 | -0.0% | |
Tax | Rs m | 12,110 | -3,634 | -333.2% | |
Profit after tax | Rs m | 31,690 | 107,256 | 29.5% | |
Gross profit margin | % | 19.4 | 27.4 | 70.9% | |
Effective tax rate | % | 27.6 | -1.2 | -2,264.6% | |
Net profit margin | % | 10.9 | 6.2 | 174.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 237,719 | 1,159,614 | 20.5% | |
Current liabilities | Rs m | 121,991 | 1,011,282 | 12.1% | |
Net working cap to sales | % | 39.9 | 8.6 | 461.9% | |
Current ratio | x | 1.9 | 1.1 | 169.9% | |
Inventory Days | Days | 17 | 91 | 18.6% | |
Debtors Days | Days | 61 | 96 | 63.2% | |
Net fixed assets | Rs m | 196,532 | 560,790 | 35.0% | |
Share capital | Rs m | 586 | 4,226 | 13.9% | |
Net worth | Rs m | 298,428 | 1,907,194 | 15.6% | |
Long term debt | Rs m | 21,349 | 877,909 | 2.4% | |
Total assets | Rs m | 438,589 | 3,923,756 | 11.2% | |
Interest coverage | x | 16.1 | 9.8 | 164.0% | |
Debt to equity ratio | x | 0.1 | 0.5 | 15.5% | |
Sales to assets ratio | x | 0.7 | 0.4 | 151.1% | |
Return on assets | % | 7.9 | 3.6 | 219.5% | |
Return on equity | % | 10.6 | 5.6 | 188.8% | |
Return on capital | % | 14.6 | 4.9 | 296.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 24,345 | 273,591 | 8.9% | |
From Investments | Rs m | -42,560 | -96,944 | 43.9% | |
From Financial Activity | Rs m | 8,004 | -328,191 | -2.4% | |
Net Cashflow | Rs m | -10,068 | -151,544 | 6.6% |
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare AUROBINDO PHARMA With: DENIS CHEM LAB AMRUTANJAN HEALTHCARE IOL CHEMICALS & PHARM. BLUE JET HEALTHCARE GSK PHARMA
After opening the day higher, Indian benchmark indices remained positive as the session progressed and ended the day on firm footing.